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I recently kicked off a biotech
venture company in Japan. This is
something unusual to see here, as
there are few university-based start-
up companies in this country.
According to one statistic, the
number of biotech venture
companies in Japan is now around
60, very many fewer than in the US
which has around 1,700. Only ten
new companies started last year and
most of them were backed by
established parent companies with
the encouragement of the Japanese
government. Indeed the Ministry of
International Trade and Industry
wants to help launch 1,000 biotech
ventures and to create 80,000 new
jobs by 2010. There is a craving for
biotech ventures but who is going to
take up the challenge?
After finishing a post-doc in the
US, I came back to Japan and
became an assistant professor in a
national university. I carried out my
research with graduate students and
post-docs, having support from my
boss and lots of collaborators. I was a
government employee in a tenured
position, secure until the retirement
age of 60 to 65. The general attitude
was: “Don’t get off the track,
develop your career along this line,
change your position only when
promoted to a better one in
academia.” The salary was low but
with the compensation of generous
pension benefits. The retirement
benefit rises simply by the number
of years you serve: this also
discourages any job change. Nobody
sees any merit in taking risks to take
a new job outside of academia. So
when I disclosed my plan to move,
my friends advised me to think
twice: some of them thought I was
giving up research.
The ‘venture’ I first joined was a
half-government and half-privately
owned company. Both sectors
decided to jointly sponsor the new
company for a fixed period of seven
years. I was recruited as a group
leader and managed a research group
that eventually grew to 20 members,
including scientists, technicians,
post-docs and graduate students.
The annual budget was much higher
than that available in university. The
package was quite good apart from
my salary, which was kept more or
less at the government rate. The
majority of the people were
dispatched from the sponsoring,
parent companies.
When I disclosed my plan to
move, my friends advised me to
think twice: some of them
thought I was giving up research
The mixture of scientists from
different backgrounds of academia
and industry was interesting and
exciting, and gave me lots of
experience. I especially appreciated
the opportunity to work with many
talented young scientists and to
collaborate with industrial colleagues
at the leading edge of biotechnology.
During that time two of my previous
colleagues switched careers to run
new biotech businesses. So indeed,
the government venture did work
as an incubator, as the sponsors
had hoped.
With two more years for the
company to go, I then contemplated
starting a real venture biotech
company. Fortunately, I met a
co-founder and a Japanese venture-
capital firm that would fund and
support a biotech company from the
start-up phase. Ours was only the
second case in the biotech field that
the company had backed.
Discussions with the members,
advisors, consultants, patent
attorneys, lawyers and other people
in the business field were different
and enlightening. I knew that I was
entering a new learning phase.
Drawing a business plan was very
interesting, and we gradually became
confident of our scheme for
developing the business. Now the
company is set up, lab and office
under construction, pre-marketing on
the way and new employees are
being recruited. A reassuring sign
was that our opening job
advertisements led to many
applicants, including medical doctors
interested in venture business after
having experience in clinical
practice. This never happened in
Japan until a few years ago.
A number of factors seem to be
changing in Japan. The government
plans to turn the national
universities into independent
administrative institutions. This is
deregulation from the central
authority that enables them to be
more independent in their own
management and decision-making.
It is expected to enhance the
flexibility and fluidity of their
organisational structures.
As for the initial movements
along this path, professors at national
universities can now take subsidiary
business roles in private companies
(to become a board member, for
example) which has long been
forbidden by the national civil law.
Also, technology licensing offices
have been established so that
intellectual property created in the
universities can properly be
transferred to industry. We are
looking forward to using this new
emerging environment.
I would surely like to see more
newcomers in this field especially
from academia. Then we might be
able to see an era in which biotech
ventures play a significant role in
research, business and the economy
of Japan.
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